Myriad Applauds the American Society of Breast Surgeons New Guidelines Recommending Genetic Testing for All People with Breast Cancer
Myriad Genetics, Inc. (MYGN)
Last myriad genetics, inc. earnings: 2/6 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
myriad.com/news-center/investor-information
Company Research
Source: GlobeNewswire
SALT LAKE CITY, Feb. 15, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced its support of the American Society of Breast Surgeons (ASBrS) new guidelines that recommend all people diagnosed with breast cancer undergo genetic testing with a multi-gene panel. “We applaud the ASBrS for recognizing important advances in scientific knowledge, and for recommending genetic testing for all people with breast cancer,” said Johnathan Lancaster, M.D., Ph.D., chief medical officer, Myriad Genetics. “The valuable information provided by genetic testing enhances physicians’ ability to select appropriate precision treatments, personalize care for patients and their families and improve health outcomes.” These new ASBrS guidelines are based on research recently published by the Targeted Medical Education (TME) Breast Care Network in the Journal of Clinical Oncology. The study demonstrated patients who met existing National C
Show less
Read more
Impact Snapshot
Event Time:
MYGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MYGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MYGN alerts
High impacting Myriad Genetics, Inc. news events
Weekly update
A roundup of the hottest topics
MYGN
News
- Why Is Myriad (MYGN) Down 1% Since Last Earnings Report? [Yahoo! Finance]Yahoo! Finance
- Myriad Genetics (MYGN) Wins Foundational Patent for MRD Assay [Yahoo! Finance]Yahoo! Finance
- Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date [Yahoo! Finance]Yahoo! Finance
- Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority DateGlobeNewswire
- Myriad Genetics Announces Patent Granted for SneakPeek® Snap Device [Yahoo! Finance]Yahoo! Finance
MYGN
Earnings
- 2/27/24 - Beat
MYGN
Sec Filings
- 3/28/24 - Form 4/A
- 3/27/24 - Form 4
- 3/25/24 - Form 4
- MYGN's page on the SEC website